INS and type 2 diabetes mellitus: Dipeptidyl peptidase 4 inhibitors (DPP-4i) (sitagliptin, vildagliptin, and linagliptin) have been shown to enhance insulin resistance in patients with type 2 diabetes mellitus by mitigating macrophage-induced inflammation without affecting insulin secretion [189,190,191].